biomarkers ATM Loss ATM Mutation BARD1 Loss BARD1 Mutation BRCA1 Loss BRCA1 Mutation BRCA2 Loss BRCA2 Mutation BRIP1 Loss BRIP1 Mutation CDK12 Loss CDK12 Mutation CHEK1 Loss CHEK1 Mutation CHEK2 Loss CHEK2 Mutation FANCL Loss FANCL Mutation PALB2 Loss PALB2 Mutation RAD51B Loss RAD51B Mutation RAD51C Loss RAD51C Mutation RAD51D Loss RAD51D Mutation RAD54L Loss RAD54L Mutation
olaparib BRCA1 Loss, +3 more biomarkers Breast Carcinoma Early stage, +1 more state Adjuvant olaparib targeted therapy
olaparib ATM Loss, +27 more biomarkers Prostate Carcinoma Castration-resistant, +1 more state Subsequent line olaparib targeted therapy
olaparib BRCA1 Loss, +3 more biomarkers Pancreatic Adenocarcinoma Metastatic Maintenance olaparib targeted therapy
olaparib BRCA1 Loss, +3 more biomarkers Fallopian Tube Carcinoma, +2 more conditions Advanced Maintenance olaparib targeted therapy
olaparib BRCA1 Loss, +3 more biomarkers Breast Carcinoma Metastatic Subsequent line olaparib targeted therapy
olaparib BRCA1 Loss, +3 more biomarkers Ovarian Carcinoma Advanced Subsequent line olaparib targeted therapy
olaparib BRCA1 Loss, +3 more biomarkers Ovarian Carcinoma Advanced Subsequent line olaparib targeted therapy
olaparib BRCA1 Loss, +3 more biomarkers Pancreatic Adenocarcinoma Metastatic Maintenance olaparib targeted therapy
olaparib BRCA1 Loss, +3 more biomarkers Fallopian Tube Carcinoma, +2 more conditions Stage II, +2 more states Maintenance olaparib targeted therapy
olaparib BRCA1 Loss, +3 more biomarkers Fallopian Tube Carcinoma, +2 more conditions Stage II, +2 more states Maintenance olaparib targeted therapy
olaparib BRCA1 Loss, +3 more biomarkers Breast Carcinoma Recurrent, +2 more states olaparib targeted therapy
olaparib BRCA2 Loss, +1 more biomarker Uterine Corpus Leiomyosarcoma Subsequent line olaparib targeted therapy